drugset / Trial / NCT05543252

An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

NCT05543252

Phase 2 Terminated 428 enrolled UCB Biopharma SRL
Non-randomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.

Timeline

Start
2022-08-29
Primary completion
2025-03-18
Completion
2025-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Minzasolmin Small molecule Oral

Indications